Aurinia Pharmaceuticals (AUPH) vs Novavax (NVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aurinia Pharmaceuticals (AUPH) has outperformed Novavax (NVAX) over the past year, gaining 40.7% versus a gain of 23.7%. Over five years, AUPH leads with a -21.1% price change compared with -93.2% for NVAX. Aurinia Pharmaceuticals is the larger company by market cap ($2.20 billion vs $2.08 billion), about 1.1 times the size, while Novavax is growing revenue faster (+64.7% vs +20.4%).
Aurinia Pharmaceuticals converts more of its revenue into profit, with a net margin of 101.5% versus 39.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | NVAX |
|---|---|---|
| Share price | $16.54 | $12.64 |
| Market cap | $2.20B | $2.08B |
| 1-day change | +1.97% | +14.80% |
| YTD return | +1.69% | +63.84% |
| 1-year return | +40.68% | +23.71% |
| 5-year return | -21.15% | -93.20% |
| P/E ratio (TTM) | 7.25 | — |
| Forward P/E | 15.51 | — |
| EPS (TTM) | $2.28 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $283.06M | $1.12B |
| Revenue growth (YoY) | +20.38% | +64.69% |
| Net income (latest FY) | $287.20M | $440.30M |
| Gross margin | 88.46% | 93.50% |
| Operating margin | 37.06% | 40.30% |
| Net margin | 101.47% | 39.19% |
| 52-week high | $19.25 | $13.39 |
| 52-week low | $10.90 | $6.20 |
| Distance from 52-week high | -14.08% | -5.60% |
| Analyst consensus | none | buy |
| Avg. price target upside | +7.98% | +10.76% |
| Average volume | 977.05K | 5.21M |
| Shares outstanding | 133.05M | 164.95M |
| Employees | 128 | 749 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUPH has outperformed NVAX by 17.0 percentage points over the past year.
- Aurinia Pharmaceuticals is more profitable, keeping 101.5 cents of every revenue dollar as net income versus 39.2 cents for Novavax.
- Novavax grew revenue faster in its latest fiscal year (+64.69% vs +20.38%).
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
AUPH vs NVAX FAQ
Which is bigger, Aurinia Pharmaceuticals or Novavax?
Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $2.20B compared with $2.08B for Novavax (NVAX).
Which stock has performed better over the past year, AUPH or NVAX?
AUPH returned +40.68% over the past 12 months, compared with +23.71% for NVAX (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Novavax in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Aurinia Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Novavax.